Each capsule contains 20 mg omeprazole.
Omeprazole (Hyposec®), a substituted benzimidazole, is one of the important drugs of a new class of orally active antiulcerants.
Omeprazole inhibits the gastric H+/K+ adenosine triphosphatase, a membrane-bound proton pump in the parietal cell, which is the final step in the secretion of gastric acid in a highly selective mechanism of action.
Hyposec® capsules contain the active ingredient (omeprazole) in the form of enteric-coated pellets to overcome the lability of omeprazole in acidic media (e.g., gastric juice), and to maintain its intragastric stability.
Hyposec® is completely metabolized by the liver and rapidly eliminated in the urine.
Although, omeprazole elimination half-life from plasma is short (60 to 90 minutes) its effect persists for 24-48 hours making it possible to be taken once daily.
- Duodenal ulcer
- Gadtric ulcer
- Reflux esophagitis
- Zollinger-Ellison Syndromer
Hypersensitivity to the drug.
Rarely, nausea, diarrhea, headache, constipation or flatulence may occur. Some mild and transient allergic reactions may occur in some patients.
Malignance possibility should be excluded before treating with Hyposec®, as the treatment may alleviate symptoms and delay diagnosis of cancer.
Hyposec®should not be given during pregnancy or lactation unless mandatory as judged by the physician.
Duodenal ulcer: 1 capsule (20 mg) once daily for 2-4 weeks. In severe cases the dose can be doubled to 2 capsules (40 mg).
Gastric ulcer or reflux esophagitis: 1 capsule (20 mg) once daily for 4-8 weeks.
Zollinger-Ellison syndrome: The recommended initial dose is 3 capsules 60 mg daily up to 120 mg daily. Doses above 80 mg should be given twice daily.
N.B. : NO dose adjustment in patients with impaired renal or liver functions, or in the elderly, is required. The use of omeprazole in children is not supported so far by a trial or a study.
Keep all medicaments out of reach of children
Product of: AMOUN PHARMACEUTICAL CO. El-Obour City, Cairo, Egypt. ATC Code: A02BC01.